Overview

Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Status:
NOT_YET_RECRUITING

Trial end date:
2029-09-01

Target enrollment:

Participant gender:

Summary

Phase III comparative, open-label, randomized (1:1) trial designed to evaluate the efficacy of reducing the total dose of PTCy to 70 mg/kg on GREFS compared to the standard dose of 100 mg/kg, in patients undergoing haploidentical HSCT for the treatment of a hematological malignancy, two years after HSCT.

Phase:

PHASE3

Details

Lead Sponsor:

Assistance Publique - Hpitaux de Paris

Treatments:

Cyclophosphamide